Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, August 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 159 articles:
HTML format


 

Single Articles

  1. LI X, He S, Tian Y, Weiss RM, et al
    Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
    Cell Signal. 2019 Jul 30:109381. doi: 10.1016/j.cellsig.2019.109381.
    Abstract    

    Abstract available

  2. CALO B, Sanguedolce F, Fortunato F, Stallone G, et al
    The impact of age on intravesical instillation of Bacille Calmette-Guerin treatment in patients with high-grade T1 bladder cancer.
    Medicine (Baltimore). 2019;98:e16223.
    Abstract    

    Abstract available

  3. YAN H, Ren S, Lin Q, Yu Y, et al
    Inhibition of UBE2N-dependent CDK6 protein degradation by miR-934 promotes human bladder cancer cell growth.
    FASEB J. 2019 Aug 2:fj201900499RR. doi: 10.1096/fj.201900499.
    Abstract    

    Abstract available

  4. REIS LO
    Non-muscle invasive bladder cancer (NMIBC): boiling arena and promissory future.
    World J Urol. 2019 Aug 1. pii: 10.1007/s00345-019-02894.
    Abstract    



  5. D'RUMMO KA, TenNapel MJ, Shen X
    The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.
    Am J Clin Oncol. 2019 Jul 25. doi: 10.1097/COC.0000000000000582.
    Abstract    

    Abstract available

  6. HIROTSU Y, Yokoyama H, Amemiya K, Hagimoto T, et al
    Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer.
    Cancer Sci. 2019 Aug 1. doi: 10.1111/cas.14155.
    Abstract    

    Abstract available

  7. KITAGAWA K, Shigemura K, Sung SY, Chen KC, et al
    Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression.
    J Cancer Res Clin Oncol. 2019 Jul 31. pii: 10.1007/s00432-019-02987.
    Abstract    

    Abstract available

  8. LEE JW, Lee S, Ho JN, Youn JI, et al
    Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells.
    Biosci Biotechnol Biochem. 2019 Jul 31:1-7. doi: 10.1080/09168451.2019.1648207.
    Abstract    

    Abstract available

  9. SAMISHINA EA, Blinova EV, Roshchin DA, Suslova IR, et al
    Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
    J Carcinog. 2019;18:3.
    Abstract    

    Abstract available

  10. QI F, Tan B, Ma F, Zhu B, et al
    A Synthetic Light-switchable System based on CRISPR Cas13a Regulates the Expression of LncRNA MALAT1 and Affects the Malignant Phenotype of Bladder Cancer Cells.
    Int J Biol Sci. 2019;15:1630-1636.
    Abstract    

    Abstract available

  11. LI A, Yao L, Fang Y, Yang K, et al
    Specifically blocking the fatty acid synthesis to inhibit the malignant phenotype of bladder cancer.
    Int J Biol Sci. 2019;15:1610-1617.
    Abstract    

    Abstract available

  12. JOSHI SR, Sheladiya A, Agrawal VN
    High thermal amplitude auto-anti-"N" complicating pretransfusion compatibility tests on a patient with malaria and bladder cancer.
    Asian J Transfus Sci. 2019;13:30-33.
    Abstract    

    Abstract available

  13. CHEN X, Li A, Sun BF, Yang Y, et al
    5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs.
    Nat Cell Biol. 2019;21:978-990.
    Abstract    

    Abstract available

  14. CHENG S, Wang G, Wang Y, Cai L, et al
    Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARgamma-mediated pathway in bladder cancer.
    Clin Sci (Lond). 2019 Jul 29. pii: CS20190587. doi: 10.1042/CS20190587.
    Abstract    

    Abstract available

  15. GENITSCH V, Kollar A, Vandekerkhove G, Blarer J, et al
    Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Urol Oncol. 2019 Jul 26. pii: S1078-1439(19)30250.
    Abstract    

    Abstract available

  16. LI Y, Zhang H, Guo Y, Cai H, et al
    A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage I-III Bladder Cancer Patients After Surgical Resection.
    Front Oncol. 2019;9:629.
    Abstract    

    Abstract available

  17. ZHANG W, Mao S, Shi D, Zhang J, et al
    MicroRNA-153 Decreases Tryptophan Catabolism and Inhibits Angiogenesis in Bladder Cancer by Targeting Indoleamine 2,3-Dioxygenase 1.
    Front Oncol. 2019;9:619.
    Abstract    

    Abstract available

  18. HABERSTROH W, Shafa S
    Pseudoachalasia secondary to metastatic bladder cancer.
    BMJ Open Gastroenterol. 2019;6:e000284.
    Abstract    

    Abstract available

  19. TIAN DW, Wu ZL, Jiang LM, Gao J, et al
    KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo.
    Dis Markers. 2019;2019:4824902.
    Abstract    

    Abstract available

  20. BAE WK, Lee HJ, Park SH, Kim JH, et al
    Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analys
    Cancer Med. 2019 Jul 29. doi: 10.1002/cam4.2446.
    Abstract    

    Abstract available

  21. BLACK PC
    Hope, hype and biology: the current biomarker landscape in bladder cancer.
    World J Urol. 2019 Jul 27. pii: 10.1007/s00345-019-02885.
    Abstract    



  22. HUPE MC, Gakis G, Seiler R
    [Molecular tumor board-urothelial cancer].
    Urologe A. 2019;58:760-767.
    Abstract    

    Abstract available

  23. MAGERS MJ, Kaimakliotis HZ, Barboza MP, Bandali E, et al
    Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
    J Clin Pathol. 2019;72:550-553.
    Abstract    

    Abstract available

  24. LIU P, Li X, Guo X, Chen J, et al
    Circular RNA DOCK1 promotes bladder carcinoma progression via modulating circDOCK1/hsa-miR-132-3p/Sox5 signalling pathway.
    Cell Prolif. 2019;52:e12614.
    Abstract    

    Abstract available

  25. AGARWAL H, Babu S, Rana C, Kumar M, et al
    Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
    Indian J Pathol Microbiol. 2019;62:244-250.
    Abstract    

    Abstract available

  26. ROMAGNOLI D, Mineo Bianchi F, Sadini P, Angiolini A, et al
    Pubis bone osteomyelitys after robotic radical cystectomy with continent intracorporeal urinary diversion: Multidisciplinary approach to a complex situation.
    Arch Ital Urol Androl. 2019;91:63-67.
    Abstract    

    Abstract available

  27. DE ROSE AF, Balzarini F, Mantica G, Toncini C, et al
    Late urinary bladder metastasis from breast cancer.
    Arch Ital Urol Androl. 2019;91:60-62.
    Abstract    

    Abstract available

  28. SODO M, Spirito L, La Rocca R, Bracale U, et al
    Partial cystectomy in young male for a urachal tumor masquerading a bladder leiomyoma.
    Arch Ital Urol Androl. 2019;91:51-52.
    Abstract    

    Abstract available

  29. MINEO BIANCHI F, Romagnoli D, D'Agostino D, Salvaggio A, et al
    Posterior muscle-fascial reconstruction and knotless urethro-neo bladder anastomosis during robot-assisted radical cystectomy: Description of the technique and its impact on urinary continence.
    Arch Ital Urol Androl. 2019;91:5-10.
    Abstract    

    Abstract available

  30. LI J, Yang F, He Q, Wang M, et al
    Laparoscopic radical cystectomy with intracorporeal ileal conduit: one center experience and clinical outcomes.
    Int Braz J Urol. 2019;45:560-571.
    Abstract    

    Abstract available

  31. FENG J, Chen K, Dong X, Xu X, et al
    Genome-wide identification of cancer-specific alternative splicing in circRNA.
    Mol Cancer. 2019;18:35.
    Abstract    

    Abstract available

  32. OKANO H, Asakawa H, Nose K, Tsuruga S, et al
    Hepatic Injury without Granulomatous Formation Associated with Intravesical Bacillus Calmette-Guerin Therapy.
    Intern Med. 2019;58:1429-1432.
    Abstract    

    Abstract available

  33. MARTINGANO D, Ramirez LC, Bjurlin MA
    Osteopathic Evaluation of Urinary Retention Caused by Atypical Presentation of Invasive Cervical Cancer Mimicking Primary Urothelial Tumor.
    J Am Osteopath Assoc. 2018;118:685-688.
    Abstract    

    Abstract available

  34. SCHWARTZ E, Faller E, Akladios CY, Greget M, et al
    Total Laparoscopic Hysterectomy for Endometriosis and an Arteriovenous Malformation.
    J Minim Invasive Gynecol. 2019;26:363-364.
    Abstract    

    Abstract available

  35. CHAN KM, Vasilev K, Shirazi HS, Mcnicholas K, et al
    Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study.
    Photodiagnosis Photodyn Ther. 2019 Aug 5. pii: S1572-1000(19)30232.
    Abstract    

    Abstract available

  36. BOSSCHIETER J, van Moorselaar RJA, Nieuwenhuijzen JA
    An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?
    Transl Androl Urol. 2019;8.
    Abstract    



  37. SHERIF A
    The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    Abstract    



  38. LEE SM
    Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes.
    Transl Androl Urol. 2019;8.
    Abstract    



  39. MIYAKE M, Owari T, Hori S, Fujimoto K, et al
    Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    Abstract    



  40. KOOL R, Joao Mansure J, Kassouf W
    Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers.
    Transl Androl Urol. 2019;8.
    Abstract    



  41. KIM J
    Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment.
    Transl Androl Urol. 2019;8.
    Abstract    



  42. SOSNOWSKI R, Kamecki H, Bjurlin MA, Przewozniak K, et al
    The diagnosis of bladder cancer: are we missing a teachable moment for smoking cessation?
    Transl Androl Urol. 2019;8.
    Abstract    



  43. SAID N
    Establishing and characterization of human and murine bladder cancer organoids.
    Transl Androl Urol. 2019;8.
    Abstract    



  44. TODENHOFER T, Seiler R
    Molecular subtypes and response to immunotherapy in bladder cancer patients.
    Transl Androl Urol. 2019;8.
    Abstract    



  45. NIEGISCH G
    Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?
    Transl Androl Urol. 2019;8.
    Abstract    



  46. AFFERI L, Zamboni S, Baumeister P, Mordasini L, et al
    Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?
    Transl Androl Urol. 2019;8.
    Abstract    



  47. MAAS M, Stenzl A
    Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?
    Transl Androl Urol. 2019;8.
    Abstract    



  48. AGARWAL A, Sonpavde G
    A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer.
    Transl Androl Urol. 2019;8.
    Abstract    



  49. DAZA J, Gul Z, Sfakianos JP
    Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis.
    Transl Androl Urol. 2019;8.
    Abstract    



  50. SINGLA N, Ghandour RA, Raj GV
    Biomarkers for platinum sensitivity in bladder cancer: are we there yet?
    Transl Androl Urol. 2019;8.
    Abstract    



  51. THOMA C
    Combining epigenetic and immune checkpoint inhibitors in bladder cancer.
    Nat Rev Urol. 2019 Aug 6. pii: 10.1038/s41585-019-0221.
    Abstract    



  52. HONG SH, Cha HJ, Hwang-Bo H, Kim MY, et al
    Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  53. DUGAS SG, Muller DC, Le Magnen C, Federer-Gsponer J, et al
    Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.
    Cancer Cytopathol. 2019 Aug 6. doi: 10.1002/cncy.22167.
    Abstract    

    Abstract available

  54. SHARIAT SF, Enikeev DV, Mostafaei H
    Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guerin unresponsive bladder cancer.
    Immunotherapy. 2019 Aug 6. doi: 10.2217/imt-2019-0083.
    Abstract    



  55. MIYAKE M, Hori S, Ohnishi S, Toritsuka M, et al
    Supplementary GM-CSF to chemotherapy and PD-L1 blockade decreases local recurrence after surgery in bladder cancer.
    Cancer Sci. 2019 Aug 5. doi: 10.1111/cas.14158.
    Abstract    

    Abstract available

  56. MIRANDA MA, Marcato PD, Carvalho IPS, Silva LB, et al
    Assessing the cytotoxic potential of glycoalkaloidic extract in nanoparticles against bladder cancer cells.
    J Pharm Pharmacol. 2019 Aug 5. doi: 10.1111/jphp.13145.
    Abstract    

    Abstract available

  57. BOFFETTA P, Borron C
    Low-Level Exposure to Arsenic in Drinking Water and Risk of Lung and Bladder Cancer: A Systematic Review and Dose-Response Meta-Analysis.
    Dose Response. 2019;17:1559325819863634.
    Abstract    

    Abstract available

  58. ZHANG J, Zhu Y, Wang Q, Kong Y, et al
    Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis.
    Urol Oncol. 2019 Aug 2. pii: S1078-1439(19)30282.
    Abstract    

    Abstract available

  59. MIRMOMEN SM, Shinagare AB, Williams KE, Silverman SG, et al
    Preoperative imaging for locoregional staging of bladder cancer.
    Abdom Radiol (NY). 2019 Aug 3. pii: 10.1007/s00261-019-02168.
    Abstract    

    Abstract available

  60. AMESTOY F, Roubaud G, Antoine M, Fonteyne V, et al
    Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer.
    Crit Rev Oncol Hematol. 2019;142:76-85.
    Abstract    



  61. SEILER R, Black PC, Williams SB, Goebell PJ, et al
    Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series.
    Urol Oncol. 2019 Jul 31. pii: S1078-1439(19)30254.
    Abstract    



  62. BORKOWSKA EM, Traczyk-Borszynska M, Kutwin P, Pietrusinski M, et al
    Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer.
    Urol Oncol. 2019 Jul 31. pii: S1078-1439(19)30239.
    Abstract    

    Abstract available

  63. KIM SJ, You D, Jeong IG, Song C, et al
    Prognosis of carcinoma in situ according to the presence of papillary bladder tumors after bacillus Calmette-Guerin immunotherapy.
    J Cancer Res Clin Oncol. 2019;145:2131-2140.
    Abstract    

    Abstract available

  64. YOSHIDA T, Shida D, Taniguchi H, Tsukamoto S, et al
    Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion.
    Ann Surg Oncol. 2019 Mar 7. pii: 10.1245/s10434-019-07276.
    Abstract    

    Abstract available

  65. ZUGAIL AS, Pinar U, Irani J
    Evaluation of pain and catheter-related bladder discomfort relative to balloon volumes of indwelling urinary catheters: A prospective study.
    Investig Clin Urol. 2019;60:35-39.
    Abstract    

    Abstract available

  66. BOYACI C, Behzatoglu K
    Diagnostic Value of Glucose Transporter 1 (GLUT-1) Expression in Nested Variant of Urothelial Carcinoma.
    Turk Patoloji Derg. 2019;35:22-27.
    Abstract    

    Abstract available

  67. DAVARO F, Schaefer J, May A, Raza J, et al
    Invasive non-urachal adenocarcinoma of the bladder: analysis of the National Cancer Database.
    World J Urol. 2019;37:497-505.
    Abstract    

    Abstract available

  68. O'DAY R, Michalova K, Campbell WG
    Bilateral Diffuse Uveal Melanocytic Proliferation Associated With Bladder Cancer: A Novel Imaging Finding.
    Ophthalmic Surg Lasers Imaging Retina. 2019;50:525-528.
    Abstract    

    Abstract available

  69. JI N, Mukherjee N, Morales EE, Tomasini ME, et al
    Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.
    Oncoimmunology. 2019;8:1614857.
    Abstract    

    Abstract available

  70. WU Q, Zhou X, Li P, Wang W, et al
    High NRBP1 expression promotes proliferation and correlates with poor prognosis in bladder cancer.
    J Cancer. 2019;10:4270-4277.
    Abstract    

    Abstract available

  71. WEI XC, Lv ZH
    MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGFbeta1/Smad2 signaling pathway in human bladder cancer.
    Onco Targets Ther. 2019;12:5937-5945.
    Abstract    

    Abstract available

  72. FISHEL ML, Xia H, McGeown J, McIlwain DW, et al
    Anti-tumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer.
    Mol Cancer Ther. 2019 Aug 14. pii: 1535-7163.MCT-18-1166.
    Abstract    

    Abstract available

  73. TSE J, Singla N, Ghandour R, Lotan Y, et al
    Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
    Expert Opin Investig Drugs. 2019 Aug 15:1-14. doi: 10.1080/13543784.2019.1655730
    Abstract    

    Abstract available

  74. SLOAN FA, Yashkin AP, Akushevich I, Inman BA, et al
    The Cost to Medicare of Bladder Cancer Care.
    Eur Urol Oncol. 2019 Feb 8. pii: S2588-9311(19)30016.
    Abstract    

    Abstract available

  75. KATES M, Nirschl TR, Baras AS, Sopko NA, et al
    Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
    Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025.
    Abstract    

    Abstract available

  76. GUILLAMON CF, Gimeno L, Server G, Martinez-Sanchez MV, et al
    Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.
    Eur Urol Oncol. 2019 May 14. pii: S2588-9311(19)30058.
    Abstract    

    Abstract available

  77. JIN H, Ying X, Que B, Wang X, et al
    N(6)-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer.
    EBioMedicine. 2019 Aug 10. pii: S2352-3964(19)30510.
    Abstract    

    Abstract available

  78. YAN H, Zhou X, Wang X, Li R, et al
    Delayed (18)F FDG PET/CT Imaging in the Assessment of Residual Tumors after Transurethral Resection of Bladder Cancer.
    Radiology. 2019 Aug 13:190032. doi: 10.1148/radiol.2019190032.
    Abstract    

    Abstract available

  79. MAR N, Dayyani F
    Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions.
    J Oncol Pract. 2019;15:421-428.
    Abstract    

    Abstract available

  80. STADLER WM
    Management of Urothelial Bladder Cancer: Predicting the Future.
    J Oncol Pract. 2019;15:429-430.
    Abstract    



  81. PANG G, Xie Q, Yao J
    Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/beta-catenin pathway.
    Oncol Lett. 2019;18:2434-2442.
    Abstract    

    Abstract available

  82. MURAKAMI K, Hamada A, Teramoto Y, Matsumoto K, et al
    Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.
    Clin Genitourin Cancer. 2019 May 30. pii: S1558-7673(19)30178.
    Abstract    

    Abstract available

  83. GONG H, Chen W, Mi L, Wang D, et al
    Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Beta-catenin pathway.
    Pharm Biol. 2019;57:507-513.
    Abstract    

    Abstract available

  84. LIU J, Liu C, Zhang X, Yu L, et al
    Anticancer sulfonamide hybrids that inhibit bladder cancer cells growth and migration as tubulin polymerisation inhibitors.
    J Enzyme Inhib Med Chem. 2019;34:1380-1387.
    Abstract    

    Abstract available

  85. WANG J, Zhang N, Peng M, Hua X, et al
    p85alpha Inactivates MMP-2 and Suppresses Bladder Cancer Invasion by Inhibiting MMP-14 Transcription and TIMP-2 Degradation.
    Neoplasia. 2019;21:908-920.
    Abstract    

    Abstract available

  86. EICH ML, Rodriguez Pena MDC, Chandrashekar DS, Chaux A, et al
    Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.
    Transl Oncol. 2019;12:1416-1424.
    Abstract    

    Abstract available

  87. DURDUX C, Fabiano E, Mejean A
    [Organ preservation by chemoradiation for bladder cancer].
    Cancer Radiother. 2019 Aug 7. pii: S1278-3218(19)30291.
    Abstract    

    Abstract available

  88. SCHULZ GB, Stief CG, Schlenker B
    [Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment].
    Urologe A. 2019 Aug 9. pii: 10.1007/s00120-019-1012.
    Abstract    

    Abstract available

  89. ADAMOWICZ J, Juszczak K, Poletajew S, van Breda SV, et al
    Scented candles as an unrecognised factor that increases the risk of bladder cancer; is there enough evidence to raise a red flag?
    Cancer Prev Res (Phila). 2019 Aug 9. pii: 1940-6207.CAPR-19-0093.
    Abstract    

    Abstract available

  90. GOAN YG, Wu WT, Liu CI, Neoh CA, et al
    Involvement of Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and the PI3K/AKT/mTOR Pathway in Nobiletin-Induced Apoptosis of Human Bladder Cancer Cells.
    Molecules. 2019;24.
    Abstract    

    Abstract available

  91. LU S, Guo M, Fan Z, Chen Y, et al
    Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.
    Am J Transl Res. 2019;11:4397-4410.
    Abstract    

    Abstract available

  92. BURGER M, Kamat AM, McConkey D
    Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?
    Eur Urol Oncol. 2019 Aug 5. pii: S2588-9311(19)30093.
    Abstract    

    Abstract available

  93. KRIPNEROVA M, Parmar HS, Pesta M, Kohoutova M, et al
    Urothelial Cancer Stem Cell Heterogeneity.
    Adv Exp Med Biol. 2019;1139:127-151.
    Abstract    

    Abstract available

  94. IKEDA J, Murakami S, Kawa G, Shibuya S, et al
    [Granulomatous Prostatitis : Three Cases Report].
    Hinyokika Kiyo. 2019;65:69-73.
    Abstract    

    Abstract available

  95. JAGUVA VASUDEVAN AA, Hoffmann MJ, Beck MLC, Poschmann G, et al
    HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  96. AUGUGLIARO M, Marvaso G, Ciardo D, Zerini D, et al
    Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?
    Neoplasma. 2019;66:160-165.
    Abstract    

    Abstract available

  97. TAARNHOJ GA, Lindberg H, Johansen C, Pappot H, et al
    Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy.
    J Patient Rep Outcomes. 2019;3:56.
    Abstract    

    Abstract available

  98. BURITY CRT, Ferreira FT, Veiga AF, Saade RD, et al
    Advanced small-cell bladder cancer into a ureterocele: A case report and literature review.
    Urol Case Rep. 2019;27:100986.
    Abstract    

    Abstract available

  99. ZOU J, Huang R, Li H, Wang B, et al
    Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells.
    Cancer Manag Res. 2019;11:6995-7006.
    Abstract    

    Abstract available

  100. HECK MM, Gschwend JE
    Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?
    Eur Urol Focus. 2019 Aug 19. pii: S2405-4569(19)30212.
    Abstract    

    Abstract available

  101. PARK C, Cha HJ, Lee H, Hwang-Bo H, et al
    Induction of G2/M Cell Cycle Arrest and Apoptosis by Genistein in Human Bladder Cancer T24 Cells through Inhibition of the ROS-Dependent PI3k/Akt Signal Transduction Pathway.
    Antioxidants (Basel). 2019;8.
    Abstract    

    Abstract available

  102. GATTA LB, Melocchi L, Bugatti M, Missale F, et al
    Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  103. JOICE GA, Bivalacqua TJ, Kates M
    Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer.
    Nat Rev Urol. 2019 Aug 21. pii: 10.1038/s41585-019-0220.
    Abstract    

    Abstract available

  104. HE A, He S, Peng D, Zhan Y, et al
    Prognostic value of long non-coding RNA signatures in bladder cancer.
    Aging (Albany NY). 2019;11.
    Abstract    

    Abstract available

  105. DARRAD MP, Syed J, Ahmed Z, Syed HA, et al
    Long-Term Prospective Outcomes Of Patients With Non-Muscle Invasive Bladder Cancer Following Holmium Laser Ablation.
    J Endourol. 2019 Aug 21. doi: 10.1089/end.2019.0253.
    Abstract    

    Abstract available

  106. LIM J, Kang SY, Park HS
    Low serum cholesterol as a risk factor for kidney and bladder cancer among Korean men: using a national cohort sample.
    Cancer Causes Control. 2019 Aug 20. pii: 10.1007/s10552-019-01219.
    Abstract    



  107. JI M, Wang Z, Chen J, Gu L, et al
    Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating beta-catenin.
    Biosci Rep. 2019 Aug 20. pii: BSR20190503. doi: 10.1042/BSR20190503.
    Abstract    

    Abstract available

  108. KAWAHARA T, Takamoto D, Miyoshi Y, Yao M, et al
    Inserting a Metallic Ureteral Stent Using an Antegrade Approach Freed a Patient from Nephrostomy Created due to Hydronephrosis Caused by Bladder Cancer.
    Case Rep Oncol. 2019;12:560-563.
    Abstract    

    Abstract available

  109. ABDOLMALEKI F, Ghafouri-Fard S, Taheri M, Omrani DM, et al
    P21-Associated ncRNA DNA Damage-Activated Expression in Bladder Cancer.
    Klin Onkol. 2019;32:277-280.
    Abstract    

    Abstract available

  110. HUANG Z, Liu G
    Research on correlations of MiR-203 expression with onset and prognosis of bladder cancer.
    J BUON. 2019;24:1210-1218.
    Abstract    

    Abstract available

  111. REN Y, Zhao C, He Y, Xu H, et al
    Long non-coding RNA bladder cancer-associated transcript 2 contributes to disease progression, chemoresistance and poor survival of patients with colorectal cancer.
    Oncol Lett. 2019;18:2050-2058.
    Abstract    

    Abstract available

  112. SHIN SS, Park YJ, Hwang B, Park SL, et al
    Triacanthine exerts antitumor effects on bladder cancer in vitro and in vivo.
    Phytomedicine. 2019;64:153069.
    Abstract    

    Abstract available

  113. HUANG HW, Yan B, Shang MX, Liu LB, et al
    [Propensity-matched comparison of laparoscopic and open radical cystectomy for female patients with bladder cancer].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51:698-705.
    Abstract    

    Abstract available

  114. YANG FL, Hong K, Zhao GJ, Liu C, et al
    [Construction of prognostic model and identification of prognostic biomarkers based on the expression of long non-coding RNA in bladder cancer via bioinformatics].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51:615-622.
    Abstract    

    Abstract available

  115. CHEN Z, He S, Zhan Y, He A, et al
    TGF-beta-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation.
    EBioMedicine. 2019 Aug 13. pii: S2352-3964(19)30528.
    Abstract    

    Abstract available

  116. CHEN FV, Koru-Sengul T, Miao F, Jue JS, et al
    Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer.
    Urol Oncol. 2019 Aug 14. pii: S1078-1439(19)30251.
    Abstract    

    Abstract available

  117. SHARMA M, Goto T, Yang Z, Miyamoto H, et al
    The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy.
    BMC Urol. 2019;19:77.
    Abstract    

    Abstract available

  118. BI H, Tian Y, Song C, Li J, et al
    Urinary microbiota - a potential biomarker and therapeutic target for bladder cancer.
    J Med Microbiol. 2019 Aug 16. doi: 10.1099/jmm.0.001058.
    Abstract    

    Abstract available

  119. ZHU CZ, Ting HN, Ng KH, Ong TA, et al
    A review on the accuracy of bladder cancer detection methods.
    J Cancer. 2019;10:4038-4044.
    Abstract    

    Abstract available

  120. REIS H, Szarvas T, Grunwald V
    [Predictive biomarkers in oncologic uropathology].
    Pathologe. 2019;40:264-275.
    Abstract    

    Abstract available

  121. YANG PJ, Hsieh MJ, Hung TW, Wang SS, et al
    Effects of Long Noncoding RNA H19 Polymorphisms on Urothelial Cell Carcinoma Development.
    Int J Environ Res Public Health. 2019;16.
    Abstract    

    Abstract available

  122. JANSEN I, Lucas M, Savci-Heijink CD, Meijer SL, et al
    Three-dimensional histopathological reconstruction of bladder tumours.
    Diagn Pathol. 2019;14:25.
    Abstract    

    Abstract available

  123. MURALI-KRISHNAN S, Pang KH, Greco F, Fiori C, et al
    Bladder-sparing treatment in MIBC: where do we stand?
    Minerva Urol Nefrol. 2019;71:101-112.
    Abstract    

    Abstract available

  124. REIS H, Szarvas T
    Urachal cancer-current concepts of a rare cancer.
    Pathologe. 2019;40.
    Abstract    

    Abstract available

  125. AKITAKE M, Yamaguchi A, Shiota M, Imada K, et al
    Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2019;39:4325-4328.
    Abstract    

    Abstract available

  126. JUNG A, Nielsen ME, Crandell JL, Palmer MH, et al
    Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study.
    BJU Int. 2019 Aug 5. doi: 10.1111/bju.14888.
    Abstract    

    Abstract available

  127. JAIN RK, Grivas P, Pal SK
    Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?
    BJU Int. 2019;124:361-362.
    Abstract    



  128. TAN WS, Sarpong R, Khetrapal P, Rodney S, et al
    Does urinary cytology have a role in haematuria investigations?
    BJU Int. 2019;123:74-81.
    Abstract    

    Abstract available

  129. TAKAHASHI T
    Overall survival is the primary endpoint in a trial of neoadjuvant chemotherapy for bladder cancer?
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32415.
    Abstract    



  130. ELANDER NO, Hussain SA
    Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30593.
    Abstract    



  131. VOSKUILEN CS, van der Heijden MS, van Rhijn BWG
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30543.
    Abstract    



  132. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    Abstract    

    Abstract available

  133. ABUFARAJ M, Foerster B, Schernhammer E, Moschini M, et al
    Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
    Eur Urol. 2019;75:649-658.
    Abstract    

    Abstract available

  134. KELLY JD, Tan WS, Porta N, Mostafid H, et al
    BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
    Eur Urol. 2019;75:593-601.
    Abstract    

    Abstract available

  135. LU M, Zhang Y, Xiao Y
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016.
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30605.
    Abstract    



  136. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    Abstract    



  137. ZHANG K, Dai H, Liang W, Zhang L, et al
    Fermented dairy foods intake and risk of cancer.
    Int J Cancer. 2019;144:2099-2108.
    Abstract    

    Abstract available

  138. TURNER MC, Gracia-Lavedan E, Cirac M, Castano-Vinyals G, et al
    Reply to: Air pollution and incident bladder cancer: a risk assessment.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32632.
    Abstract    



  139. KAWADA T
    Air pollution and incident bladder cancer: a risk assessment.
    Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32633.
    Abstract    



  140. YOSHIDA T, Kates M, Fujita K, Bivalacqua TJ, et al
    Predictive biomarkers for drug response in bladder cancer.
    Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082.
    Abstract    

    Abstract available

  141. FUJIMURA T
    Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14076.
    Abstract    

    Abstract available

  142. TEISHIMA J, Matsubara A
    Editorial Comment to Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer.
    Int J Urol. 2019 Jul 30. doi: 10.1111/iju.14086.
    Abstract    



  143. KOJIMA T
    Editorial Comment from Dr Kojima to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, inductio
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14074.
    Abstract    



  144. CHANG SS
    Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    J Urol. 2019 Jul 31:10109701JU00005794560657170.
    Abstract    



  145. CHANG SS
    Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model.
    J Urol. 2019 Jul 31:101097JU0000000000000479. doi: 10.1097/JU.0000000000000479.
    Abstract    



  146. CHANG SS
    Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    J Urol. 2019 Jul 31:10109701JU00005794608369953.
    Abstract    



  147. BJURLIN MA, Nielsen ME
    Editorial Comment.
    J Urol. 2019;202:246.
    Abstract    



  148. WEI L, Hussein AA, Ma Y, Azabdaftari G, et al
    Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.
    J Urol. 2019;201:1105-1114.
    Abstract    

    Abstract available

  149. RICHARD PO, Bashir S, Riverin BD, Alibhai SMH, et al
    Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study.
    J Urol. 2019;202:319-325.
    Abstract    

    Abstract available

  150. LAGUNA MP
    Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2019;202:456-457.
    Abstract    



  151. VANTAKU V, Putluri V, Bader DA, Maity S, et al
    Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
    Oncogene. 2019 Aug 5. pii: 10.1038/s41388-019-0902.
    Abstract    

    Abstract available

  152. WANG F, Li Y, Shan F, Zhang Q, et al
    Upregulation of JMJD2A promotes migration and invasion in bladder cancer through regulation of SLUG.
    Oncol Rep. 2019 Jul 23. doi: 10.3892/or.2019.7246.
    Abstract    

    Abstract available

  153. TOLLE A, Buckendahl L, Jung K
    Plasma miR15b5p and miR5905p for distinguishing patients with bladder cancer from healthy individuals.
    Oncol Rep. 2019 Jul 24. doi: 10.3892/or.2019.7247.
    Abstract    

    Abstract available

  154. LI F, Guo H, Yang Y, Feng M, et al
    Autophagy modulation in bladder cancer development and treatment (Review).
    Oncol Rep. 2019 Aug 21. doi: 10.3892/or.2019.7286.
    Abstract    

    Abstract available

  155. BABOUDJIAN M, Lechevallier E, Michel F, Ben Othman K, et al
    [Does diagnostic ureterorenoscopy increase the risk of bladder recurrence after total nephroureterectomy? A review of the literature].
    Prog Urol. 2019;29:138-146.
    Abstract    

    Abstract available

  156. KAUSHIK D, Wang H, Michalek J, Liss MA, et al
    Chemoradiation Versus Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Propensity Score-Weighted Comparative Analysis Using the National Cancer Database.
    Urology. 2019 Aug 8. pii: S0090-4295(19)30701.
    Abstract    

    Abstract available

  157. LIN-BRANDE M, Pearce SM, Ashrafi AN, Nazemi A, et al
    Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer.
    Urology. 2019 Aug 14. pii: S0090-4295(19)30721.
    Abstract    

    Abstract available

  158. JIANG WD, Yuan PC
    Molecular network-based identification of competing endogenous RNAs in bladder cancer.
    PLoS One. 2019;14:e0220118.
    Abstract    

    Abstract available

  159. KAWAHARA T, Kojima T, Kandori S, Kurobe M, et al
    TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
    PLoS One. 2019;14:e0220173.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;